Painting a new picture in surgical oncology, together

We’re changing the present and improving the future of cancer treatment

Innovation in surgical oncology that will change everything

We paint innovative biomedical solutions to address unmet needs in oncology

Cebiotex is an innovative biotechnology start-up, a spin-off from the Universitat Politècnica de Catalunya (UPC) and the Hospital Sant Joan de Déu de Barcelona (HSJD).

Our objective is to offer innovative and effective biomedical solutions that help surgeons improve their operations; bringing them closer to excellence, and enhancing the life and treatment of cancer patients.

Cutting-edge technology for the control and local treatment of cancer

We come up with solutions that improve surgical performance and the treatment of cancer patients.

We have created a new medical product using our own technology in nanofiber engineering, together with the medical teams and scientists from the Hospital Sant Joan de Déu and the technological teams from the Universitat Politècnica de Catalunya.

We’re working on the development of the CEB-01 drug to address unmet medical needs in the oncology field, and to assure both surgeons and patients that the area operated on is now free from cancer cells.

At Cebiotex we believe that technology can change lives

“We are concerned about cancer in general, and we concern ourselves with childhood cancer”

Joan Bertran

Experience for and commitment to changing the current panorama of cancer treatment

We design solutions with the conviction that things, regarding surgical cancer treatment, can always change for the better

Principal Investigators, Clinical Trial

News

In this section you can read
more about Cebiotex

Poster Presentation at ASCO 2024 Annual Meeting

CEB-01 Phase-1 clinical trial progress presented at CTOS 2023

CEB-01 Phase-1 clinical trial progress presented at ESMO 2023

Published paper Biomaterials Dec 2015

Poster ESSO40 – CEB-01-RLS01

338211 CEB-01-RLS01 ASCO 21

Together we are stronger against cancer

We paint real solutions for real needs, but we’re missing you

Our aim is that both pediatric and adult patients will be able to benefit from the CEB-01 drug in their oncological treatments, while prioritizing the pediatric line during its development.

Currently, our drug is in Clinical Phase-I (security-dosis), and has had extremely promising results.

After performing security studies with the first 9 of 21 patients, we will be able to reach our biggest aim to date: starting clinical trials with pediatric patients, hand-in-hand with the Hospital Sant Joan de Déu.
In order to achieve it and advance our work, your participation is essential.